Amgen and its portfolio of 11 biosimilars is standing behind interchangeability, saying the designation should not be rescinded and that the FDA needs to retain its regulatory flexibilities.
The position puts Amgen in opposition to bipartisan legislation that’s pushing to remove the interchangeability designation for biosimilars and to the…
Click here to view original post
